Not recruiting

Study of erdafitinib treatment for adults and adolescents with advanced solid tumors having FGFR gene changes

Verified siteInvestigationalNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with advanced solid tumors who have specific genetic changes called FGFR gene alterations. The study will test a medication called erdafitinib (also known as JNJ-42756493), which is given as a film-coated tablet that patients take by mouth.

The purpose of this research is to evaluate how well erdafitinib works in treating advanced solid tumors in both adult and pediatric patients (children and teenagers 6 years and older). The study includes patients whose tumors have specific genetic changes in the FGFR genes, which are alterations that can affect how tumors grow and spread.

During the study, participants will receive erdafitinib tablets daily for treatment periods of 21 days. The maximum daily dose is 9 milligrams. Doctors will monitor how the tumors respond to the treatment using specialized imaging techniques to measure any changes in tumor size. The study will track whether tumors shrink completely, partially, or show no response to the treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial assessment
Your doctor will confirm if you have an advanced solid tumor with specific FGFR gene changes
Basic health checks will be performed, including blood tests to verify your bone marrow, liver, and kidney function
Your general physical condition will be evaluated using a standardized scale
Step 2
Treatment preparation
Your current symptoms must be stable or mild before starting the treatment
Your phosphate levels will be checked within 14 days before starting treatment
Step 3
Medication administration
You will receive erdafitinib in the form of film-coated tablets
The medication needs to be taken by mouth
Your doctor will provide specific instructions about the dosage and timing
Step 4
Regular monitoring
Your tumor response will be regularly assessed using imaging scans
Blood tests will be performed to monitor your body's response to treatment
Your doctor will check for any side effects during treatment
Step 5
Treatment continuation
Treatment will continue as long as your disease does not worsen
Regular evaluations will determine if the treatment is working
The study is planned to continue until October 2026

Who can join the trial?

10 criteria

Must be at least 6 years of age
Must have an advanced solid tumor (cancer that has spread) with specific genetic changes called FGFR mutations or fusions
Must have cancer that can be measured using standard imaging tests
Must have received at least one previous cancer treatment for advanced disease, unless you are a child or teenager with a newly diagnosed tumor that has no standard treatment options
Must not have any remaining side effects from previous cancer treatments, except for hair loss, nerve problems, or certain laboratory test results
Must have documented cancer progression (worsening of the disease) before starting the study screening process. This does not apply to children who have not received previous treatment
For adults (18 years and older): Must be able to perform daily activities with minimal assistance (ECOG performance status of 0 or 1)
For children and teenagers (6 to 17 years): Must have a Karnofsky Score of 70 or higher, which means they can care for themselves but may not be able to carry on normal activities
Must have adequate bone marrow, liver, and kidney function as shown by specific blood test results
Must be willing and able to provide informed consent. For children and teenagers, parents or legal representatives must provide consent, and the young participant must also agree to participate

Who cannot join the trial?

12 criteria

History of urothelial tumors (cancers that start in the lining of the urinary system)
Lack of confirmed FGFR gene alterations (specific genetic changes in the FGFR genes)
Previous treatment with FGFR inhibitors (medications that target FGFR gene alterations)
Presence of untreated brain metastases (cancer that has spread to the brain)
Severe heart conditions or uncontrolled high blood pressure
Significant liver or kidney dysfunction
Active infections requiring systemic treatment (medications that affect the whole body)
Other ongoing cancer treatments that might interfere with the study medication
Pregnancy or breastfeeding
Unable to swallow oral medications
History of other cancers within the past 2 years (except for successfully treated non-melanoma skin cancer or cervical cancer in situ)
Major surgery within 4 weeks before starting the study treatment

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Verified
Asklepios Kliniken Hamburg GmbH
Hamburg, Germany

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Erdafitinib is a targeted therapy medication used to treat advanced solid tumors. It specifically works by targeting abnormalities in FGFR genes (Fibroblast Growth Factor Receptor). This medication is designed to help patients whose tumors have specific genetic changes called FGFR mutations or fusions. It can be used in both adult and pediatric patients, including adolescents, who have these specific genetic markers in their tumors.

Erdafitinib

What is already known about the treatment

Erdafitinib – An oral targeted therapy medication that belongs to the class of FGFR (Fibroblast Growth Factor Receptor) inhibitors, taken in tablet form. This drug works by blocking specific proteins called FGFR that can be abnormally active in cancer cells, particularly in patients with certain genetic alterations in their FGFR genes. It is currently being investigated in clinical trials for the treatment of various advanced solid tumors, showing particular promise in patients who have specific FGFR gene mutations or fusions. The medication represents a targeted approach to cancer treatment, aiming to affect cancer cells that carry specific genetic changes while potentially having less impact on healthy cells.

Investigated diseases

Advanced Solid Tumors
A condition where abnormal cells form solid masses or tumors that have spread beyond their original location in the body. These tumors can develop in various organs and tissues, including bones, muscles, or organs. The tumors grow and multiply in an uncontrolled manner, potentially affecting surrounding tissues. Advanced solid tumors are characterized by their progression beyond the initial site where they first appeared. They may involve multiple areas of the body and can vary in size and growth rate.
FGFR Gene Alterations
A genetic condition where changes occur in the Fibroblast Growth Factor Receptor genes, which are responsible for cell growth and division. These alterations can affect how cells develop and multiply in the body. The changes in FGFR genes can be present from birth or develop over time. FGFR gene alterations can affect various parts of the body since these genes play important roles in tissue development and maintenance.